Concurrent Investment Advisors LLC Buys 1,438 Shares of Becton, Dickinson and Company (NYSE:BDX)

Concurrent Investment Advisors LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 15.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,750 shares of the medical instruments supplier’s stock after purchasing an additional 1,438 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,439,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $29,000. Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $33,000. Tompkins Financial Corp lifted its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the period. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $46,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.2 %

Shares of BDX stock opened at $227.54 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market capitalization of $65.34 billion, a PE ratio of 37.80, a PEG ratio of 1.63 and a beta of 0.40. The stock has a fifty day simple moving average of $232.90 and a two-hundred day simple moving average of $233.29.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BDX shares. Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Barclays upped their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $278.29.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the completion of the transaction, the executive vice president now owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the sale, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock valued at $2,370,309 in the last 90 days. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.